The U.S. government has approved 10 manufacturers to participate in a 340B pilot that replaces upfront discounts with a rebate model for certain providers. The shift represents one of the most consequential changes to 340B economics in years, with direct implications for how specialty therapies flow through covered entities. Stakeholders should watch how rebate mechanics affect cash flow for safety-net providers and whether the model expands beyond the pilot cohort.
Eli Lilly is bringing LillyDirect to Australia to deliver Mounjaro straight to patients' doors, bypassing local pharmacies. The move has drawn pushback from Australian doctors and pharmacists concerned about disintermediation.
Beam Therapeutics has filed suit alleging a former scientist stole confidential information to launch a competing rare disease base editing program at YolTech. Serapha Bio, which licensed the therapy, denies the allegations.
U.S. tariffs on imported patented medicines and ingredients expanded September 29 to reach mid-sized and smaller manufacturers excluded from the first round. Industry groups warn of mounting R&D and supply pressure.
HHS is offering funding to teams with innovative trial designs as it weighs moving beyond the traditional phased clinical trial system. The effort comes amid concerns about Chinese competition in drug development.
A pharmacist argues in a STAT opinion piece that 340B law must adapt to orphan-designated drugs that carry multiple uses. Current rules create losses and ambiguity for pharmacies navigating the orphan exclusion.
FDA chief nominee Overton told lawmakers she would 'follow the law' on vaccine decisions and work to speed early-stage drug R&D. Her positions on key pharma issues drew scrutiny at her Senate hearing.
Ten drugmakers have been approved for a 340B pilot allowing rebates to certain providers in place of upfront discounts. The change could reshape cash flow and reconciliation for covered entities.
As AI agents take on more autonomous roles in drug R&D, a single uncaught error can cascade into downstream decisions, raising the stakes for validation and human oversight. For patient-facing access operations, the same principle applies: automation must be paired with auditable checkpoints so that one wrong input never silently propagates through eligibility, benefits, or affordability decisions.
The move toward rebate-based 340B models signals that program complexity will only increase, not decrease. Access programs that invest now in reconciliation, eligibility verification, and real-time data integration will be far better positioned to protect patient affordability as the discount-to-rebate transition unfolds.
Manufacturer-direct delivery models are expanding globally and will inevitably reach more complex specialty categories. The winners will be those who preserve the clinical oversight, benefits coordination, and adherence support that specialty patients depend on, rather than simply compressing the supply chain for convenience.
